Biological and methodological features of the measurement of S100B, a putative marker of brain injury
The S100B astroglial protein is widely used as a parameter of glial activation and/or death in several conditions of brain injury. Cerebrospinal fluid and serum S100B variations have been proposed to evaluate clinical outcomes in these situations. Here, we briefly broach some aspects, commonly not s...
Gespeichert in:
| Veröffentlicht in: | Clinical biochemistry 2008-07, Vol.41 (10), p.755-763 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 763 |
|---|---|
| container_issue | 10 |
| container_start_page | 755 |
| container_title | Clinical biochemistry |
| container_volume | 41 |
| creator | Gonçalves, Carlos-Alberto Concli Leite, Marina Nardin, Patrícia |
| description | The S100B astroglial protein is widely used as a parameter of glial activation and/or death in several conditions of brain injury. Cerebrospinal fluid and serum S100B variations have been proposed to evaluate clinical outcomes in these situations. Here, we briefly broach some aspects, commonly not sufficiently valorized, concerning the biology and measurements of this protein. S100B has molecular targets and activities in and outside of astrocytes, and variations of intra and extracellular content are not necessarily coupled. We discuss the extracellular origin of this protein in brain tissue, as well as extracerebral sources of this protein in serum, comparing it with other available protein markers of brain damage. The superestimation of the heterodimer S100A1-B in the current clinical literature is also analyzed. We affirm that poor dualistic views that consider S100B elevation as “bad” or “good” simplify clinical practice and delay our comprehension of the role of this protein, both in physiological conditions and in brain disorders. |
| doi_str_mv | 10.1016/j.clinbiochem.2008.04.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69211411</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0009912008001562</els_id><sourcerecordid>69211411</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-98abefe376b5d1636f42d4fdbce2d25dca32e31a56688e30bdd08ba53398c2f63</originalsourceid><addsrcrecordid>eNqNkU2P1DAMhiMEYoeFv4DKhRMtzkezyZEdLSzSShyAc5QmLpOhbYYkXWn_PRnNCLgtJ8v2Y7-yX0LeUOgoUPl-37kpLEOIbodzxwBUB6ID4E_Ihqor3jLN-VOyAQDdasrggrzIeV9TJpR8Ti6oEr3Qgm4IXoc4xR_B2amxi29mLLvo_5RGtGVNmJs4NmWHtW1zzWdcyrH0lQJcv2tsc1iLLeG-Ajb9xHTsDcmGpQnLfk0PL8mz0U4ZX53jJfn-8ebb9ra9-_Lp8_bDXesEyNJqZQcckV_JofdUcjkK5sXoB4fMs947yxlyansplUIOg_egBttzrpVjo-SX5O1p7yHFXyvmYuaQHU6TXTCu2UjNKBWUPgoyUL0GzSqoT6BLMeeEozmkUI98MBTM0QyzN_-YYY5mGBCmmlFnX59F1mFG_3fy_P0KbE8A1p_cB0wmu4CLQx8SumJ8DP8h8xuo96G5</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20859092</pqid></control><display><type>article</type><title>Biological and methodological features of the measurement of S100B, a putative marker of brain injury</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Gonçalves, Carlos-Alberto ; Concli Leite, Marina ; Nardin, Patrícia</creator><creatorcontrib>Gonçalves, Carlos-Alberto ; Concli Leite, Marina ; Nardin, Patrícia</creatorcontrib><description>The S100B astroglial protein is widely used as a parameter of glial activation and/or death in several conditions of brain injury. Cerebrospinal fluid and serum S100B variations have been proposed to evaluate clinical outcomes in these situations. Here, we briefly broach some aspects, commonly not sufficiently valorized, concerning the biology and measurements of this protein. S100B has molecular targets and activities in and outside of astrocytes, and variations of intra and extracellular content are not necessarily coupled. We discuss the extracellular origin of this protein in brain tissue, as well as extracerebral sources of this protein in serum, comparing it with other available protein markers of brain damage. The superestimation of the heterodimer S100A1-B in the current clinical literature is also analyzed. We affirm that poor dualistic views that consider S100B elevation as “bad” or “good” simplify clinical practice and delay our comprehension of the role of this protein, both in physiological conditions and in brain disorders.</description><identifier>ISSN: 0009-9120</identifier><identifier>EISSN: 1873-2933</identifier><identifier>DOI: 10.1016/j.clinbiochem.2008.04.003</identifier><identifier>PMID: 18454941</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adipocyte ; Alzheimer's disease ; Antibody Specificity ; Astrocyte ; Biomarkers - analysis ; Brain Injuries - diagnosis ; Brain Injuries - pathology ; Brain injury ; Humans ; Immunoassay ; Nerve Growth Factors - analysis ; Nerve Growth Factors - genetics ; Reproducibility of Results ; RNA, Messenger - genetics ; S100 Calcium Binding Protein beta Subunit ; S100 Proteins - analysis ; S100 Proteins - genetics ; S100B protein ; Transcription, Genetic</subject><ispartof>Clinical biochemistry, 2008-07, Vol.41 (10), p.755-763</ispartof><rights>2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-98abefe376b5d1636f42d4fdbce2d25dca32e31a56688e30bdd08ba53398c2f63</citedby><cites>FETCH-LOGICAL-c406t-98abefe376b5d1636f42d4fdbce2d25dca32e31a56688e30bdd08ba53398c2f63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.clinbiochem.2008.04.003$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18454941$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gonçalves, Carlos-Alberto</creatorcontrib><creatorcontrib>Concli Leite, Marina</creatorcontrib><creatorcontrib>Nardin, Patrícia</creatorcontrib><title>Biological and methodological features of the measurement of S100B, a putative marker of brain injury</title><title>Clinical biochemistry</title><addtitle>Clin Biochem</addtitle><description>The S100B astroglial protein is widely used as a parameter of glial activation and/or death in several conditions of brain injury. Cerebrospinal fluid and serum S100B variations have been proposed to evaluate clinical outcomes in these situations. Here, we briefly broach some aspects, commonly not sufficiently valorized, concerning the biology and measurements of this protein. S100B has molecular targets and activities in and outside of astrocytes, and variations of intra and extracellular content are not necessarily coupled. We discuss the extracellular origin of this protein in brain tissue, as well as extracerebral sources of this protein in serum, comparing it with other available protein markers of brain damage. The superestimation of the heterodimer S100A1-B in the current clinical literature is also analyzed. We affirm that poor dualistic views that consider S100B elevation as “bad” or “good” simplify clinical practice and delay our comprehension of the role of this protein, both in physiological conditions and in brain disorders.</description><subject>Adipocyte</subject><subject>Alzheimer's disease</subject><subject>Antibody Specificity</subject><subject>Astrocyte</subject><subject>Biomarkers - analysis</subject><subject>Brain Injuries - diagnosis</subject><subject>Brain Injuries - pathology</subject><subject>Brain injury</subject><subject>Humans</subject><subject>Immunoassay</subject><subject>Nerve Growth Factors - analysis</subject><subject>Nerve Growth Factors - genetics</subject><subject>Reproducibility of Results</subject><subject>RNA, Messenger - genetics</subject><subject>S100 Calcium Binding Protein beta Subunit</subject><subject>S100 Proteins - analysis</subject><subject>S100 Proteins - genetics</subject><subject>S100B protein</subject><subject>Transcription, Genetic</subject><issn>0009-9120</issn><issn>1873-2933</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU2P1DAMhiMEYoeFv4DKhRMtzkezyZEdLSzSShyAc5QmLpOhbYYkXWn_PRnNCLgtJ8v2Y7-yX0LeUOgoUPl-37kpLEOIbodzxwBUB6ID4E_Ihqor3jLN-VOyAQDdasrggrzIeV9TJpR8Ti6oEr3Qgm4IXoc4xR_B2amxi29mLLvo_5RGtGVNmJs4NmWHtW1zzWdcyrH0lQJcv2tsc1iLLeG-Ajb9xHTsDcmGpQnLfk0PL8mz0U4ZX53jJfn-8ebb9ra9-_Lp8_bDXesEyNJqZQcckV_JofdUcjkK5sXoB4fMs947yxlyansplUIOg_egBttzrpVjo-SX5O1p7yHFXyvmYuaQHU6TXTCu2UjNKBWUPgoyUL0GzSqoT6BLMeeEozmkUI98MBTM0QyzN_-YYY5mGBCmmlFnX59F1mFG_3fy_P0KbE8A1p_cB0wmu4CLQx8SumJ8DP8h8xuo96G5</recordid><startdate>20080701</startdate><enddate>20080701</enddate><creator>Gonçalves, Carlos-Alberto</creator><creator>Concli Leite, Marina</creator><creator>Nardin, Patrícia</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>20080701</creationdate><title>Biological and methodological features of the measurement of S100B, a putative marker of brain injury</title><author>Gonçalves, Carlos-Alberto ; Concli Leite, Marina ; Nardin, Patrícia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-98abefe376b5d1636f42d4fdbce2d25dca32e31a56688e30bdd08ba53398c2f63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adipocyte</topic><topic>Alzheimer's disease</topic><topic>Antibody Specificity</topic><topic>Astrocyte</topic><topic>Biomarkers - analysis</topic><topic>Brain Injuries - diagnosis</topic><topic>Brain Injuries - pathology</topic><topic>Brain injury</topic><topic>Humans</topic><topic>Immunoassay</topic><topic>Nerve Growth Factors - analysis</topic><topic>Nerve Growth Factors - genetics</topic><topic>Reproducibility of Results</topic><topic>RNA, Messenger - genetics</topic><topic>S100 Calcium Binding Protein beta Subunit</topic><topic>S100 Proteins - analysis</topic><topic>S100 Proteins - genetics</topic><topic>S100B protein</topic><topic>Transcription, Genetic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gonçalves, Carlos-Alberto</creatorcontrib><creatorcontrib>Concli Leite, Marina</creatorcontrib><creatorcontrib>Nardin, Patrícia</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical biochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gonçalves, Carlos-Alberto</au><au>Concli Leite, Marina</au><au>Nardin, Patrícia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biological and methodological features of the measurement of S100B, a putative marker of brain injury</atitle><jtitle>Clinical biochemistry</jtitle><addtitle>Clin Biochem</addtitle><date>2008-07-01</date><risdate>2008</risdate><volume>41</volume><issue>10</issue><spage>755</spage><epage>763</epage><pages>755-763</pages><issn>0009-9120</issn><eissn>1873-2933</eissn><abstract>The S100B astroglial protein is widely used as a parameter of glial activation and/or death in several conditions of brain injury. Cerebrospinal fluid and serum S100B variations have been proposed to evaluate clinical outcomes in these situations. Here, we briefly broach some aspects, commonly not sufficiently valorized, concerning the biology and measurements of this protein. S100B has molecular targets and activities in and outside of astrocytes, and variations of intra and extracellular content are not necessarily coupled. We discuss the extracellular origin of this protein in brain tissue, as well as extracerebral sources of this protein in serum, comparing it with other available protein markers of brain damage. The superestimation of the heterodimer S100A1-B in the current clinical literature is also analyzed. We affirm that poor dualistic views that consider S100B elevation as “bad” or “good” simplify clinical practice and delay our comprehension of the role of this protein, both in physiological conditions and in brain disorders.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>18454941</pmid><doi>10.1016/j.clinbiochem.2008.04.003</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-9120 |
| ispartof | Clinical biochemistry, 2008-07, Vol.41 (10), p.755-763 |
| issn | 0009-9120 1873-2933 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69211411 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adipocyte Alzheimer's disease Antibody Specificity Astrocyte Biomarkers - analysis Brain Injuries - diagnosis Brain Injuries - pathology Brain injury Humans Immunoassay Nerve Growth Factors - analysis Nerve Growth Factors - genetics Reproducibility of Results RNA, Messenger - genetics S100 Calcium Binding Protein beta Subunit S100 Proteins - analysis S100 Proteins - genetics S100B protein Transcription, Genetic |
| title | Biological and methodological features of the measurement of S100B, a putative marker of brain injury |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T18%3A02%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biological%20and%20methodological%20features%20of%20the%20measurement%20of%20S100B,%20a%20putative%20marker%20of%20brain%20injury&rft.jtitle=Clinical%20biochemistry&rft.au=Gon%C3%A7alves,%20Carlos-Alberto&rft.date=2008-07-01&rft.volume=41&rft.issue=10&rft.spage=755&rft.epage=763&rft.pages=755-763&rft.issn=0009-9120&rft.eissn=1873-2933&rft_id=info:doi/10.1016/j.clinbiochem.2008.04.003&rft_dat=%3Cproquest_cross%3E69211411%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20859092&rft_id=info:pmid/18454941&rft_els_id=S0009912008001562&rfr_iscdi=true |